bpc+tb blend vs klow

updated October 25, 2026

bpc+tb blend (tier A) vs klow (tier A): what each is, why each got its grade, half-life and source counts side by side.

the difference

checked October 25, 2026

in a retrospective knee-pain chart review with follow-up by phone, four patients received bpc-157 with thymosin beta-4 (TB4) and three reported significant improvement; the review had no untreated or placebo group.

• Lee E, Padgett B. Altern Ther Health Med 2021 (PMID 34324435)

a PubMed search and a ClinicalTrials.gov search on October 24, 2026 found no controlled human trial of either blend.

• PubMed search: BPC-157 with TB-500 or thymosin beta-4 (October 24, 2026)
• ClinicalTrials.gov search: BPC-157 and its aliases (October 24, 2026)
• ClinicalTrials.gov search: KPV (October 24, 2026)

FDA describes tb-500 as N-acetyl-LKKTETQ, a seven-amino-acid fragment of thymosin beta-4, and its briefing for the July 2026 advisory committee found no published study of kpv products used in humans.

• FDA presentations, Pharmacy Compounding Advisory Committee, July 23, 2026 (BPC-157, KPV, TB-500)
• FDA briefing document, KPV, Pharmacy Compounding Advisory Committee, July 2026

in July 2026, FDA proposed keeping bpc-157, tb-500 and kpv off the 503A bulks list for pharmacy compounding, and its review says none of the three is a component of an FDA-approved drug. FDA's advisory committee then voted on all three; news reports put the vote on each at 8-6-1 in favor of adding it, and the committee's recommendations are non-binding.

• FDA presentations, Pharmacy Compounding Advisory Committee, July 23, 2026 (BPC-157, KPV, TB-500)
• FDA briefing document, BPC-157, Pharmacy Compounding Advisory Committee, July 2026
• FDA briefing document, KPV, Pharmacy Compounding Advisory Committee, July 2026
• FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026

bpc+tb blend · tier A

the wolverine stack. bpc-157 + tb-500. coherent repair logic, heavy clinic folklore, zero controlled trials on the blend.

tier rationale

A-tier because both components have unusually strong preclinical stories for the repair category and the pairing is mechanistically coherent. not S-tier because the blend has no drug-grade formal evidence, no phase 3 package, no FDA approval, and no controlled human tendon-recovery trial. A reflects a strong mechanism plus persistent real-world signal, not certainty.

klow · tier A

four-peptide clinic blend for skin, hair, collagen, and recovery. component logic first; blend evidence still missing.

tier rationale

a compounded blend of four peptides, each with its own mechanism: KPV (anti-inflammatory tripeptide from α-MSH) + GHK-Cu (collagen/skin) + BPC-157 (tissue/GI healing) + TB-500 (actin-binding, cell migration). the blend emerged from peptide clinic culture as an extension of the wolverine stack, adding cosmetic and anti-inflammatory components. A-tier because the mechanisms are genuinely complementary and the outcome pattern across compounding-pharmacy use is consistent. not S-tier because no controlled trial exists on the combination, and the component evidence is not uniformly S/A-tier.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.